Pacira BioSciences (PCRX) Competitors $25.42 -0.43 (-1.64%) As of 03:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRKShould you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry. Pacira BioSciences vs. Its Competitors Perrigo Supernus Pharmaceuticals Nektar Therapeutics Omeros Assembly Biosciences Cumberland Pharmaceuticals Eli Lilly and Company Johnson & Johnson AbbVie Merck & Co., Inc. Perrigo (NYSE:PRGO) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, media sentiment, analyst recommendations, valuation and risk. Which has better earnings & valuation, PRGO or PCRX? Pacira BioSciences has lower revenue, but higher earnings than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerrigo$4.37B0.75-$171.80M-$0.58-41.08Pacira BioSciences$705.85M1.62-$99.56M-$2.78-9.14 Which has more volatility and risk, PRGO or PCRX? Perrigo has a beta of 0.47, indicating that its stock price is 53% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500. Do analysts prefer PRGO or PCRX? Perrigo presently has a consensus price target of $33.00, indicating a potential upside of 38.51%. Pacira BioSciences has a consensus price target of $30.83, indicating a potential upside of 21.32%. Given Perrigo's higher possible upside, equities analysts plainly believe Perrigo is more favorable than Pacira BioSciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perrigo 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Pacira BioSciences 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Is PRGO or PCRX more profitable? Perrigo has a net margin of -1.86% compared to Pacira BioSciences' net margin of -18.08%. Pacira BioSciences' return on equity of 13.29% beat Perrigo's return on equity.Company Net Margins Return on Equity Return on Assets Perrigo-1.86% 9.09% 3.96% Pacira BioSciences -18.08%13.29%6.61% Do insiders and institutionals believe in PRGO or PCRX? 95.9% of Perrigo shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.4% of Perrigo shares are held by company insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media refer more to PRGO or PCRX? In the previous week, Perrigo had 13 more articles in the media than Pacira BioSciences. MarketBeat recorded 17 mentions for Perrigo and 4 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.71 beat Perrigo's score of 1.36 indicating that Pacira BioSciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Perrigo 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pacira BioSciences 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryPacira BioSciences beats Perrigo on 11 of the 16 factors compared between the two stocks. Get Pacira BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PCRX vs. The Competition Export to ExcelMetricPacira BioSciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.14B$3.06B$5.76B$9.75BDividend YieldN/A2.24%4.40%4.10%P/E Ratio-9.1621.0030.8325.91Price / Sales1.62392.25469.77121.46Price / Cash5.9943.2325.7828.79Price / Book1.519.739.466.03Net Income-$99.56M-$54.08M$3.27B$265.29M7 Day Performance2.11%3.12%2.37%2.86%1 Month Performance12.71%4.57%3.88%1.23%1 Year Performance79.11%10.22%30.52%19.11% Pacira BioSciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PCRXPacira BioSciences3.363 of 5 stars$25.42-1.6%$30.83+21.3%+82.1%$1.14B$705.85M-9.16720News CoveragePositive NewsPRGOPerrigo4.9782 of 5 stars$23.05+1.5%$33.00+43.2%-16.3%$3.12B$4.37B-39.738,379News CoveragePositive NewsAnalyst DowngradeSUPNSupernus Pharmaceuticals2.2701 of 5 stars$42.99+0.7%$41.00-4.6%+28.3%$2.39B$665.13M37.38580News CoverageNKTRNektar Therapeutics4.2971 of 5 stars$27.43+0.6%$88.33+222.0%+33.5%$518.45M$98.43M-3.12220OMEROmeros4.1795 of 5 stars$4.22-4.3%$18.00+326.5%+3.8%$272.37MN/A-2.00210Gap UpASMBAssembly Biosciences4.1765 of 5 stars$25.76+1.3%$38.67+50.1%+84.3%$195.18M$28.52M-4.62100Positive NewsCPIXCumberland Pharmaceuticals0.344 of 5 stars$3.07-1.9%N/A+138.4%$46.83M$37.87M-13.9580Analyst DowngradeLLYEli Lilly and Company4.9992 of 5 stars$698.89-0.3%$950.17+36.0%-25.4%$663.68B$45.04B45.6847,000Trending NewsAnalyst UpgradeJNJJohnson & Johnson4.8743 of 5 stars$176.26-0.2%$174.50-1.0%+9.1%$425.41B$88.82B18.85138,100Trending NewsOptions VolumeABBVAbbVie4.7591 of 5 stars$206.23-0.2%$214.95+4.2%+6.4%$365.13B$56.33B98.2155,000Trending NewsMRKMerck & Co., Inc.4.9977 of 5 stars$84.21flat$107.44+27.6%-25.2%$210.34B$64.17B12.9875,000Positive News Related Companies and Tools Related Companies Perrigo Competitors Supernus Pharmaceuticals Competitors Nektar Therapeutics Competitors Omeros Competitors Assembly Biosciences Competitors Cumberland Pharmaceuticals Competitors Eli Lilly and Company Competitors Johnson & Johnson Competitors AbbVie Competitors Merck & Co., Inc. Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PCRX) was last updated on 8/25/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pacira BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pacira BioSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access